Samsung Biologics
-
Samsung Biologics reportedly pondering prospects in cell & gene therapy
SOUTH KOREA – Samsung Biologics CEO John Rim has said the South Korean biotech will explore the possibility of adding cell and gene therapy to…
-
Samsung Biologics grabs US$81M contract manufacturing deal with Novartis
SOUTH KOREA – Samsung Biologics and Novartis have signed an initial US$81 million contract manufacturing and development agreement, marking the first time the two companies…
-
Samsung Biologics shells US$2.3 bln to complete acquisition of Samsung Bioepis
SOUTH KOREA – Samsung Biologics has completed the US$2.3 billion acquisition of Biogen’s stake in the Samsung Bioepis joint venture. Samsung Biologics signed a stake…
-
Samsung Biologics buys out Biogen in biosim venture for US$2.3B
SOUTH KOREA – Samsung Biologics announced that it has agreed to pay US$2.3 billion for Biogen’s stake in their nearly decade-long biosimilars joint venture Samsung…
-
Demand surge for Covid-19 antibody prompts GSK, Vir to ramp up output
USA – To meet rising demand, GlaxoSmithKline and partner Vir Biotechnology are increasing output of their COVID-19 antibody treatment sotrovimab at a second plant. The…
-
Samsung Biologics rolls out the supply of domestically-manufactured Moderna vaccines in South Korea
SOUTH KOREA – Samsung Biologics, a major South Korean contract drug manufacturer, has rolled out supplies of the first batch of domestically-made Moderna vaccines. Moderna’s…